belatacept, CAS No.rp173527, Fusion protein of CD80;Fusion protein of CD86

Features and benefits
    Item Number
    rp173527
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp173527-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp173527-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90

    Basic Description

    Product Namebelatacept, CAS No.rp173527
    GradeMoligand™
    Specifications & PurityMoligand™
    Action TypeINHIBITOR
    Mechanism of actionFusion protein of CD80;Fusion protein of CD86

    Associated Targets(Human)

    CD86 Tclin T-lymphocyte activation antigen CD86 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    CD80 Tclin T-lymphocyte activation antigen CD80 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp173527

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Latek R, Fleener C, Lamian V, Kulbokas 3rd E, Davis PM, Suchard SJ, Curran M, Vincenti F, Townsend R.  (2009)  Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation..  Transplantation,  87  (6): (926-33).  [PMID:19300198] [10.1021/op500134e]
    2. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS et al..  (2016)  Belatacept and Long-Term Outcomes in Kidney Transplantation..  N Engl J Med,  374  (4): (333-43).  [PMID:26816011] [10.1021/op500134e]

    Solution Calculators